[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Follicular Lymphoma Treatment Market, 2012-2023

January 2018 | 203 pages | ID: F6999F1C149EN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Follicular Lymphoma Treatment Market: By Treatment Type (Chemotherapy, Targeted Therapy, Radiotherapy, Monoclonal Antibodies, Stem Cell Transplantation), By Route of Administration (Oral, Parenteral), By End-User (Hospitals, Oncology Centers, Academic Research Institutes) and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Market Outline: Follicular Lymphoma Treatment Market

Follicular lymphoma is the second most common indolent non-Hodgkin’s lymphoma and it develops when the body makes abnormal B-lymphocytes in lymph nodes. The symptoms associated with follicular lymphoma include enlargement of lymph nodes in neck, abdomen, and groin, weight loss, difficulties in breathing, fatigue, and night sweats. Follicular lymphoma is diagnosed by biopsy, blood tests, and X-rays among others. Follicular lymphoma can be treated with chemotherapy, radiation therapy, targeted therapy, and stem cell transplant.

Market Dynamics: Follicular Lymphoma Treatment Market

Rise in prevalence of follicular lymphoma, family history of blood disorders, increase in R&D activities for the innovation of newer drugs, and technological advancements in disease diagnosis are anticipated to fuel the follicular lymphoma treatment market. Moreover, promising pipeline products, innovation of newer therapies such as monoclonal antibodies, and government initiations for the cancer management are expected to boost the market over the forecast period. However, stringent regulatory policies for drug approval, the high cost of treatment, and adverse effects associated with the treatment are expected to hamper the growth of follicular lymphoma treatment market over the forecast years.

Market Scope: Follicular Lymphoma Treatment Market

Follicular lymphoma treatment market is segmented on the basis of treatment type, route of administration, end user, and region

Based on the treatment type, the market is segmented into the following:
  • Chemotherapy
  • Alkylating Agents
  • Nucleoside Analogues
  • Anthracycline Derivatives
  • Others
  • Radiotherapy
  • Monoclonal Antibodies
  • Stem Cell Transplantation
Based on the route of administration, the market is segmented into the following:
  • Oral
  • Parenteral
  • Others
Based on the end user, the market is segmented into the following:
  • Hospitals
  • Retail Pharmacies
  • Oncology Centers
  • Academic Research Institutes
Based on region, the market is segmented into the following:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Summary: Follicular Lymphoma Treatment Market

Follicular lymphoma treatment market is poised to grow at significant rate owing to increase in the R&D activities for the innovation newer therapies and drugs. Most of the international players are actively involved in the development of newer products. For instance, in December 2015, Novartis announced phase IIa study results of CTL019 used in the treatment of certain types of lymphoma including follicular lymphoma. Moreover, rising adoption of monoclonal antibodies for targeted therapies propels the follicular lymphoma treatment market. Furthermore, acquisitions and mergers, collaborations, product approvals, and product launchings are the strategies followed by the market players for gaining larger revenue share in follicular lymphoma treatment market. For instance, in February 2017, Health Canada approved Roche’s Gazyva (Obinutuzumab) for patients with previously treated follicular lymphoma. In addition, in August 2017, Epizyme, Inc. and US Oncology Research are collaborated to identify the non-Hodgkin lymphoma patients with EZH2 mutations and eligible patients are directed to ongoing phase 2 clinical trial of Tazemetostast in diffuse large B-cell lymphoma and follicular lymphoma.

Regional Analysis: Follicular Lymphoma Treatment Market

Geographically, global follicular lymphoma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America follicular lymphoma treatment market is poised to grow at notable rate due to increase in the prevalence of follicular lymphoma (according to American Cancer Society, approximately 20% of follicular lymphoma cases observed among all types lymphoma patients), increase in R&D activities for the innovation of newer drugs, an increase in healthcare expenditure in the region. Europe follicular lymphoma treatment market is expected to grow significantly due to the adoption of newer therapies, sophisticated healthcare infrastructure, an increase in the prevalence of follicular lymphoma due to change in lifestyle in the region. Asia Pacific follicular lymphoma treatment market has a lucrative growth owing to the large patient pool, increase in awareness about lymphoma treatment, and government initiations for the prevention of cancer are expected to fuel the market in the region. Latin America follicular lymphoma treatment market expected to grow at moderate rate due to the expansion of business into the region by market players, adoption of newer drugs, and economic growth are bolster the market. Middle East and Africa follicular lymphoma treatment market have a growth attributed to rising in awareness about lymphoma treatment, increase in the prevalence of follicular lymphoma, and growing per capita income.

Competition Assessment: Follicular Lymphoma Treatment Market

Some of the players in the global follicular lymphoma treatment market include:
  • Hoffmann La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Merck & Co. Inc. (U.S.)
  • AbbVie, Inc. (U.S.)
  • Bayer AG (Germany)
  • Epizyme Inc. (U.S.)
  • Bristol Myers Squibb (U.S.)
  • Johnson and Johnson Services Inc. (U.S.)
Notable Market Developments: Follicular Lymphoma Treatment Market

In October 2017, U.S. Food and Drug Administration approved Bayer AG’s Aliqopa (Copanlisib) for the treatment of follicular lymphoma
1. EXECUTIVE SUMMARY

2. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET INTRODUCTION

2.1. Global Follicular Lymphoma Treatment Market – Taxonomy
2.2. Global Follicular Lymphoma Treatment Market –Definitions
  2.2.1. Treatment Type
  2.2.2. Route of Administration
  2.2.3. End-User

3. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Follicular Lymphoma Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Follicular Lymphoma Treatment Market – Regulations
  3.6.1. U.S.
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Follicular Lymphoma Treatment Market – Treatment Type Pipeline Analysis

4. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Chemotherapy
  5.1.1. Alkylating Agents
    5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.1.3. Market Opportunity Analysis
  5.1.2. Nucleoside Analogues
    5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.2.3. Market Opportunity Analysis
  5.1.3. Anthracycline Derivatives
    5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.3.3. Market Opportunity Analysis
  5.1.4. Others
    5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.4.3. Market Opportunity Analysis
5.2. Radiotherapy
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Monoclonal Antibodies
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Stem Cell Transplantation
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis

6. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Oral
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Parenteral
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Others
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospitals
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Oncology Centers
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Academic Research Institutes
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis

8. GLOBAL FOLLICULAR LYMPHOMA TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User, and Region, 2017 – 2023

9. NORTH AMERICA FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Chemotherapy
    9.1.1.1. Alkylating Agents
    9.1.1.2. Nucleoside Analogues
    9.1.1.3. Anthracycline Derivatives
    9.1.1.4. Others
  9.1.2. Radiotherapy
  9.1.3. Monoclonal Antibodies
  9.1.4. Stem Cell Transplantation
9.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.2.1. Oral
  9.2.2. Parenteral
  9.2.3. Others
9.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Hospitals
  9.3.2. Retail Pharmacies
  9.3.3. Oncology Centers
  9.3.4. Academic Research Institutes
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023
9.6. North America Follicular Lymphoma Treatment Market Dynamics – Trends

10. EUROPE FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Chemotherapy
    10.1.1.1. Alkylating Agents
    10.1.1.2. Nucleoside Analogues
    10.1.1.3. Anthracycline Derivatives
    10.1.1.4. Others
  10.1.2. Radiotherapy
  10.1.3. Monoclonal Antibodies
  10.1.4. Stem Cell Transplantation
10.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Oral
  10.2.2. Parenteral
  10.2.3. Others
10.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Hospitals
  10.3.2. Retail Pharmacies
  10.3.3. Oncology Centers
  10.3.4. Academic Research Institutes
10.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Germany
  10.4.2. UK
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Russia
  10.4.7. Poland
  10.4.8. Rest of Europe
10.5. Europe Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023
10.6. Europe Follicular Lymphoma Treatment Market Dynamics – Trends

11. ASIA-PACIFIC FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Chemotherapy
    11.1.1.1. Alkylating Agents
    11.1.1.2. Nucleoside Analogues
    11.1.1.3. Anthracycline Derivatives
    11.1.1.4. Others
  11.1.2. Radiotherapy
  11.1.3. Monoclonal Antibodies
  11.1.4. Stem Cell Transplantation
11.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Oral
  11.2.2. Parenteral
  11.2.3. Others
11.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Hospitals
  11.3.2. Retail Pharmacies
  11.3.3. Oncology Centers
  11.3.4. Academic Research Institutes
11.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  11.4.1. Japan
  11.4.2. China
  11.4.3. India
  11.4.4. ASEAN
  11.4.5. Australia & New Zealand
  11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023
11.6. Asia-Pacific Follicular Lymphoma Treatment Market Dynamics – Trends

12. LATIN AMERICA FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Chemotherapy
    12.1.1.1. Alkylating Agents
    12.1.1.2. Nucleoside Analogues
    12.1.1.3. Anthracycline Derivatives
    12.1.1.4. Others
  12.1.2. Radiotherapy
  12.1.3. Monoclonal Antibodies
  12.1.4. Stem Cell Transplantation
12.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Oral
  12.2.2. Parenteral
  12.2.3. Others
12.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Hospitals
  12.3.2. Retail Pharmacies
  12.3.3. Oncology Centers
  12.3.4. Academic Research Institutes
12.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Argentina
  12.4.4. Venezuela
  12.4.5. Rest of Latin America
12.5. Latin America Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023
12.6. Latin America Follicular Lymphoma Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA FOLLICULAR LYMPHOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Chemotherapy
    13.1.1.1. Alkylating Agents
    13.1.1.2. Nucleoside Analogues
    13.1.1.3. Anthracycline Derivatives
    13.1.1.4. Others
  13.1.2. Radiotherapy
  13.1.3. Monoclonal Antibodies
  13.1.4. Stem Cell Transplantation
13.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Oral
  13.2.2. Parenteral
  13.2.3. Others
13.3. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Hospitals
  13.3.2. Retail Pharmacies
  13.3.3. Oncology Centers
  13.3.4. Academic Research Institutes
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.4.1. Gulf Cooperation Council (GCC) Countries
  13.4.2. Israel
  13.4.3. South Africa
  13.4.4. Rest of MEA
13.5. MEA Follicular Lymphoma Treatment Market - Opportunity Analysis Index, By Treatment, By Route of Administration, By End-User and Country, 2017 – 2023
13.6. MEA Follicular Lymphoma Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Treatment Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Hoffmann La Roche Ltd. (Switzerland)
  14.2.2. Novartis AG (Switzerland)
  14.2.3. GlaxoSmithKline plc (U.K.)
  14.2.4. Merck & Co. Inc. (U.S.)
  14.2.5. AbbVie, Inc. (U.S.)
  14.2.6. Bayer AG (Germany)
  14.2.7. Epizyme Inc. (U.S.)
  14.2.8. Bristol Myers Squibb (U.S.)
  14.2.9. Johnson and Johnson Services Inc. (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS


More Publications